In vitro release behavior and cytotoxicity of doxorubicin-loaded gold nanoparticles in cancerous cells.
Doxorubicin (DOX), a common cancer chemotherapeutics, was conjugated to folate-modified thiolated-polyethylene glycol-functionalized gold nanoparticles. The in vitro, controlled release behavior of DOX-loaded gold nanoparticles was observed using porous dialysis membranes (cut-off = 2 kDa). DOX-loaded gold nanoparticles had higher cytotoxicity for folate-receptor-positive cells (KB cells) compared to folate-receptor-negative cells (A549 cells) which were 48 and 62% viable for 10 microM doxorubicin, respectively. This indicates the potential of these nano-carriers for targeted-delivery. In addition, healthy cell viability was 69% for 10 microM free doxorubicin whereas for the same content of drug in DOX-loaded nanoparticles healthy cell viability increased to 80%.
Asadishad
B
B
Department of Chemical and Petroleum Engineering, Sharif University of Technology, Tehran, Iran.
Vossoughi
M
M
Alamzadeh
I
I
D000970:Antineoplastic Agents / Q000493:pharmacokinetics* / Q000494:pharmacology; D002352:Carrier Proteins / Q000378:metabolism; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000187:drug effects; D004317:Doxorubicin / Q000493:pharmacokinetics* / Q000494:pharmacology; D004337:Drug Carriers; D016503:Drug Delivery Systems / Q000379:methods*; D058973:Folate Receptors, GPI-Anchored; D005492:Folic Acid / Q000378:metabolism*; D006046:Gold / Q000494:pharmacology*; D006801:Humans; D053758:Nanoparticles; D011956:Receptors, Cell Surface / Q000378:metabolism
D000970:Antineoplastic Agents; D002352:Carrier Proteins; D004337:Drug Carriers; D058973:Folate Receptors, GPI-Anchored; D011956:Receptors, Cell Surface; D006046:Gold; D004317:Doxorubicin; D005492:Folic Acid